Research Summary Current treatment of malignancy is hindered by tumor cell heterogeneity and progressive clonal evolution. I MHC expression.
Effects are nontoxic, reversible, and transcend species and tissue barriers.
Treated melanoma and hepatoma cells exhibited striking cytoskeletal reorganization, including changes in an actin-binding substrate for phosphorylation by the EGF receptor. This new inhibitor appears to favorably alter the biologic balance between tumor and host by reducing heterogeneity, restoring sensitivity to normal environmental signals governing growth, and inducing surface markers which alert and facilitate host response. We have partially purified this inhibitor and distinguished it from other known tumor inhibitors. Our laboratory's focus is on completing purification, well under way, and developing a new, powerful, nontoxic, biologically rational, and more effective therapy for currently incurable cancers. Related Images Image 1 Treatment of hamster melanoma in vivo.